MEI Pharma Reports New Data Showing High Response Rates in Clinical Trial of Pracinostat and Azacitidine in Myelodysplastic

 MEI Pharma Reports New Data Showing High Response Rates in Clinical Trial of
           Pracinostat and Azacitidine in Myelodysplastic Syndrome

Data Accepted for Presentation at American Society of Hematology Annual
Meeting

PR Newswire

SAN DIEGO, Nov. 6, 2012

SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, announced today that preliminary data from a pilot Phase II clinical
trial of the Company's investigational oral histone deacetylase (HDAC)
inhibitor, Pracinostat, in combination with azacitidine in patients with
advanced myelodysplastic syndrome (MDS) has been accepted for poster
presentation at the American Society of Hematology Annual Meeting on December
10, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

An abstract of the presentation, entitled "Very high rates of clinical and
cytogenetic response with the combination of the histone deacetylase inhibitor
Pracinostat (SB939) and 5-azacitidine in high-risk myelodysplastic syndrome,"
submitted by Dr. Quintas-Cardama and Dr. Garcia-Manero of the MD Anderson
Cancer Center, is now available online at www.hematology.org. The poster will
be presented at 6:00 p.m. Eastern time from Hall B1-B2, Level 1, Building B of
the Georgia World Congress Center in Atlanta.

"We are very encouraged not only by the response rates reported to date, but
also by the rapid appearance of the responses with the combination of
Pracinostat and azacitidine," said Daniel P. Gold, Ph.D., President and Chief
Executive Officer of MEI Pharma. "These data are particularly compelling given
that most patients in the study had treatment-related MDS and expressed
high-risk cytogenetic abnormalities, both of which carry a poor prognosis.
With these data in hand, combined with the capital raise we announced
yesterday, we expect to be in a position to rapidly advance to the next stage
of development and initiate a randomized Phase II trial of Pracinostat in
combination with azacitidine in patients with MDS by the second quarter of
next year."

About Pracinostat

Pracinostat is a selective inhibitor of a group of enzymes called histone
deacetylases (HDAC). There are currently two HDAC inhibitors approved by the
U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell
lymphoma, one of which is also approved for the treatment of peripheral T-cell
lymphoma. Pracinostat has shown evidence of single-agent activity in multiple
clinical trials, including advanced hematologic malignancies such as MDS,
acute myeloid leukemia and myelofibrosis. Pracinostat has also demonstrated
pre-clinical activity in hematologic disorders and solid tumors when used
alone or in combination with a wide range of therapies in laboratory studies.
Pracinostat has been generally well tolerated in clinical testing of more than
150 patients, with readily manageable side effects often associated with drugs
of this class. The most common adverse event (all grades) is fatigue.
Pracinostat has not been approved by the FDA for commercial distribution.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's
clinical development pipeline includes lead drug candidate Pracinostat, a
potential best-in-class HDAC inhibitor. Pracinostat has been tested in
multiple Phase I and exploratory Phase II clinical trials, including advanced
hematologic malignancies such as MDS, acute myeloid leukemia and
myelofibrosis. The Company expects to initiate a randomized Phase II trial of
Pracinostat in combination with azacitidine in patients with MDS by the second
quarter of 2013. In addition, MEI Pharma is developing two drug candidates
derived from its isoflavone-based technology platform, ME-143 and ME-344.
Results from a Phase I trial of intravenous ME-143 in heavily treated patients
with solid refractory tumors were presented at the American Society of
Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of
intravenous ME-344 in patients with solid refractory tumors is ongoing. For
more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.

SOURCE MEI Pharma, Inc.

Website: http://www.meipharma.com
Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, +1-858-792-3729, pdespain@meipharma.com